Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Spero Therapeutics has raised $105.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in July 2026.
Spero Therapeutics's investors include RA Capital Management, Pfizer, National Science Foundation, Rock Springs Capital, SR One.
Spero Therapeutics is headquartered in Cambridge, United States.
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Spero Therapeutics is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Spero Therapeutics — Funding & Investors." VCBacked, July 14, 2026, https://www.vcbacked.co/company/spero-therapeutics. Accessed September 2, 2026.
VCBacked. (2026). Spero Therapeutics — Funding & Investors. Retrieved September 2, 2026, from https://www.vcbacked.co/company/spero-therapeutics
{{cite web |title=Spero Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/spero-therapeutics |website=VCBacked |access-date=September 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated